[Neoadjuvant or Adjuvant Chemotherapy for Bladder Cancer?]
Related Experiment Video
Updated: Apr 10, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
M C Hupe1, M W Kramer1, M A Kuczyk1
1Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.
Abstract:
Advanced urothelial carcinoma of the bladder is associated with a high metastatic potential. Life expectancy for metastatic patients is poor and rarely exceeds more than one year without further therapy. Neoadjuvant chemotherapy can decrease the tumour burden while reducing the risk of death. Adjuvant chemotherapy has been discussed controversially. Patients with lymph node-positive metastases seem to benefit the most from adjuvant chemotherapy. In selected patients, metastasectomy can prolong survival. In metastastic patients, the combination of gemcitabine and cisplatin has become the new standard regimen due to a lower toxicity in comparison to the combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). For second-line treatment, vinflunine is the only approved therapeutic agent.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Calculi VI: Surgical Management
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Imaging Studies VI: Voiding Cystourethrography and Cystography
Kidney Transplant II: Surgical Procedure
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...

